Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib ± Toripalimab Adjuvant Therapy in Intermediate-High Risk Renal Cancer
ChiCTR2500101854Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in clear cell renal cell carcinoma (ccRCC) comparing Vorolanib + Toripalimab with Vorolanib monotherapy (2 arms). Primary endpoint: Two-year disease-free survival rate. Started Apr 2025; status: recruiting.
02
Drugs
vorolanibtoripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2500101854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101854.